Clinical application of stem cell in cardiovascular diseases

Hyun-Jae Kang; Young-Bae Park; Hyo-Soo Kim

doi:10.5124/jkma.2011.54.5.462

Journal List > J Korean Med Assoc > v.54(5) > 1042431

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kang, Park, and Kim: Clinical application of stem cell in cardiovascular diseases

Focused Issue of This Month

Stem Cells

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2011; 54(5): 462-467.

Published online: 11 May 2011

DOI: https://doi.org/10.5124/jkma.2011.54.5.462

Clinical application of stem cell in cardiovascular diseases

Hyun-Jae Kang, MD, Young-Bae Park, MD, Hyo-Soo Kim, MD

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author: Hyo-Soo Kim, hyosoo@snu.ac.kr

Received 22 February 2011 Accepted 10 March 2011

(open-access):

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cardiovascular disease has been one of leading causes of death and has an increasing importance in Korea. However the current treatment modalities for cardiovascular disease have limited efficacy. To overcome the limitations of current therapies, stem cell therapy has been evaluated as a new therapeutic option. Most experience and achievements of stem cell therapy for clinical applications have come from bone marrow-derived stem cells. Recent meta-analyses showed that stem cell therapy is safe and effective for improving cardiac systolic functions in patients with acute myocardial infarction. However, the long term efficacy and effects on clinical outcomes need to be determined. Stem cell therapy for acute cardiovascular disease, especially for acute myocardial infarction, has a proven efficacy and safety in short term follow up. Newer stem cell sources and therapeutic approaches such as adjunctive therapy or pretransplantation cultivation will be applied in this field to improve the efficacy of stem cell therapy. Stem cell therapy is a promising new therapeutic option for cardiovascular disease.

Keywords: Stem cell therapy, Cardiovascular diseases, Myocardial infarction

Figures and Tables

Table 1

Key randomized controlled trials for myocardial infarction

LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; SPECT, single photon emission computed tomography; LV, left ventricular; G-CSF, granulocyte-colony stimulating factor.

References

1. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004. 94:92–95.

2. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004. 364:141–148.

3. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maer-tens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006. 367:113–121.

4. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006. 355:1199–1209.

5. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006. 355:1210–1221.

6. Meluzin J, Mayer J, Groch L, Janousek S, Hornácek I, Hlinomaz O, Kala P, Panovsky R, Prasek J, Kaminek M, Stanicek J, Klabusay M, Korístek Z, Navratil M, Dusek L, Vinklarkova J. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J. 2006. 152:975.e9–975.e15.

7. Kang HJ, Lee HY, Na SH, Chang SA, Park KW, Kim HK, Kim SY, Chang HJ, Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB, Kim HS. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation. 2006. 114:1 Suppl. I145–I151.

8. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagege AA. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008. 117:1189–1200.

9. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007. 50:1761–1767.

TOOLS

Similar articles